Feng Chi Biotech (6744.TWO) Stock Price

Feng Chi Biotech Corp. generates revenue through the sale of prenatal and neonatal testing reagents and instruments, genetic testing analysis and development services, research instruments and reagents, and industrial microbiology and food testing reagents. The company's products are primarily sold to markets in Taiwan, China mainland, Japan, South Korea, Southeast Asia, and India, as well as other overseas regions. These services and products target healthcare providers, research institutions, and food safety regulators within these regions. The firm focuses on delivering comprehensive testing solutions across life science and microbiological applications for both clinical and industrial use cases. The company's product portfolio includes specialized reagents and instruments for prenatal and newborn screening, genetic analysis, and microbiological testing. These offerings are tailored to meet the needs of healthcare facilities and laboratories in the specified geographic markets. By providing end-to-end testing services and equipment, Feng Chi Biotech Corp. serves the growing demand for accurate diagnostic tools in reproductive health, genetic research, and food safety sectors. Feng Chi Biotech Corp. operates within the life science and microbiological testing services sector, offering a range of products that support prenatal care, neonatal screening, genetic research, and industrial food testing. The company's international sales strategy targets key regions in Asia, including Taiwan, China mainland, Japan, South Korea, Southeast Asia, and India, where healthcare and food safety regulations require regular testing. Their business model centers on providing reliable diagnostic solutions to medical and industrial clients across these markets.